Pharmacy Services
Interferon Gamma-1b (Actimmune) - Early Termination of Trial for Idiopathic Pulmonary Fibrosis
March 9, 2007
The INSPIRE trial evaluating interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis was terminated early due to lack of benefit. In an interim analysis, more patient died who were treated with interferon gamma-1b (14.5%) compared to patients treated with placebo (12.7%).
Additional information can be obtained at the following links:
- MedWatch Alert:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150450.htm - Public Health Advisory:
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051286.html - Drug Information Page:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109130.htm
Updated
March 9, 2007; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.
Social Media
Copyright © 2013 University of Utah Health Care